Accordingly, PPARγ and CEBPα are extensively utilized as targets for the development of anti-obesity drugs through the inhibition of adipogenesis, both in vitro and in vivo [22]. The gene discussed is CEBPA; the disease is obesity due to melanocortin 4 receptor deficiency.